Patent ID: 8377921

Claim:
A method for treating a condition mediated by anaplastic lymphoma kinase, comprising administering to a subject in need of treatment, a therapeutically effective amount of a compound of Formula (2), or pharmaceutically acceptable salts thereof; wherein R 1 is halo or C 1-6 alkyl; R 2 is H; R 3 is (CR 2 ) 0-2 SO 2 R 12 ; R 4 is C 1-6 alkyl, C 2-6 alkenyl or C 2-6 alkynyl; OR 12 , NR(R 12 ), halo, nitro, SO 2 R 12 , (CR 2 ) p R 13 or X; or R 4 is H; R 6 is isopropoxy or methoxy; one of R 8 and R 9 is (CR 2 ) q Y and the other is C 1-6 alkyl, cyano, C(O)O 0-1 R 12 , CONR(R 12 ) or CONR(CR 2 ) p NR(R 12 ); X is (CR 2 ) q Y, cyano, C(O)O 0-1 R 12 , CONR(R 12 ), CONR(CR 2 ) p NR(R 12 ), CONR(CR 2 ) p OR 12 , CONR(CR 2 ) p SR 12 , CONR(CR 2 ) p S(O) 1-2 R 12 or (CR 2 ) 1-6 NR(CR 2 ) p OR 12 ; Y is pyrrolidinyl, piperidinyl or azetidinyl, each of which is attached to the phenyl ring via a carbon atom; R 12 and R 13 are independently 3-7 membered saturated or partially unsaturated carbocyclic ring, or a 5-7 membered heterocyclic ring comprising N, O and/or S; aryl or heteroaryl; or R 12 is H or C 1-6 alkyl; R is H or C 1-6 alkyl; n is 0-1; p is 0-4; and q is 0; and optionally in combination with a second therapeutic agent, wherein said condition is anaplastic large cell lymphoma, ALK+ non-Hodgkin's lymphoma, inflammatory myofibrolastic tumor, neuroblastoma or a neoplastic disease, wherein said neoplastic disease is non-small cell lung cancer.